Table of Contents Author Guidelines Submit a Manuscript
Table of Contents Alerts

To receive news and publication updates for Oxidative Medicine and Cellular Longevity, enter your email address in the box below.

Oxidative Medicine and Cellular Longevity
Volume 2016 (2016), Article ID 7453849, 7 pages
http://dx.doi.org/10.1155/2016/7453849
Research Article

Resveratrol Reduces the Incidence of Portal Vein System Thrombosis after Splenectomy in a Rat Fibrosis Model

Meng Xu,1 Wanli Xue,2 Zhenhua Ma,1 Jigang Bai,1 and Shengli Wu1

1Department of Hepatobiliary Surgery, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China
2Department of Public Health, Xi’an Jiaotong University School of Medicine, Xi’an 710061, China

Received 1 April 2016; Accepted 7 June 2016

Academic Editor: Jerzy Kruk

Copyright © 2016 Meng Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. P. Starr and D. Raines, “Cirrhosis: diagnosis, management, and prevention,” American Family Physician, vol. 84, no. 12, pp. 1353–1359, 2011. View at Google Scholar · View at Scopus
  2. D. Ganem and A. M. Prince, “Hepatitis B virus infection—natural history and clinical consequences,” The New England Journal of Medicine, vol. 350, no. 11, pp. 1118–1129, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Haché and J.-P. Villeneuve, “Lamivudine treatment in patients with chronic hepatitis B and cirrhosis,” Expert Opinion on Pharmacotherapy, vol. 7, no. 13, pp. 1835–1843, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Parikh, R. Shah, and P. Kapoor, “Portal vein thrombosis,” American Journal of Medicine, vol. 123, no. 2, pp. 111–119, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Pietrabissa, C. Moretto, G. Antonelli, L. Morelli, E. Marciano, and F. Mosca, “Thrombosis in the portal venous system after elective laparoscopic splenectomy,” Surgical Endoscopy and Other Interventional Techniques, vol. 18, no. 7, pp. 1140–1143, 2004. View at Google Scholar · View at Scopus
  6. K. M. Stamou, K. G. Toutouzas, P. B. Kekis et al., “Prospective study of the incidence and risk factors of postsplenectomy thrombosis of the portal, mesenteric, and splenic veins,” Archives of Surgery, vol. 141, no. 7, pp. 663–669, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Charco, J. Fuster, C. Fondevila, J. Ferrer, E. Mans, and J. C. García-Valdecasas, “Portal vein thrombosis in liver transplantation,” Transplantation Proceedings, vol. 37, no. 9, pp. 3904–3905, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. R. A. Mesa, D. S. Nagorney, S. Schwager, J. Allred, and A. Tefferi, “Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic,” Cancer, vol. 107, no. 2, pp. 361–370, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. E. R. Winslow, L. M. Brunt, J. A. Drebin, N. J. Soper, M. E. Klingensmith, and E. Dunn, “Portal vein thrombosis after splenectomy,” American Journal of Surgery, vol. 184, no. 6, pp. 631–636, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Ikeda, M. Sekimoto, S. Takiguchi et al., “High incidence of thrombosis of the portal venous system after laparoscopic splenectomy: a prospective study with contrast-enhanced CT scan,” Annals of Surgery, vol. 241, no. 2, pp. 208–216, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Kinjo, H. Kawanaka, T. Akahoshi et al., “Risk factors for portal venous thrombosis after splenectomy in patients with cirrhosis and portal hypertension,” British Journal of Surgery, vol. 97, no. 6, pp. 910–916, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Tripodi, M. Primignani, V. Chantarangkul et al., “An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis,” Gastroenterology, vol. 137, no. 6, pp. 2105–2111, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Tripodi and P. M. Mannucci, “The coagulopathy of chronic liver disease,” The New England Journal of Medicine, vol. 365, no. 2, pp. 147–156, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Soyer, A. O. Ciftci, F. C. Tanyel, M. E. Şenocak, and N. Büyükpamukçu, “Portal vein thrombosis after splenectomy in pediatric hematologic disease: risk factors, clinical features, and outcome,” Journal of Pediatric Surgery, vol. 41, no. 11, pp. 1899–1902, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Namasivayam, “Chemoprevention in experimental animals,” Annals of the New York Academy of Sciences, vol. 1215, no. 1, pp. 60–71, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. J. A. Baur and D. A. Sinclair, “Therapeutic potential of resveratrol: the in vivo evidence,” Nature Reviews Drug Discovery, vol. 5, no. 6, pp. 493–506, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. E. L. Robb, M. M. Page, B. E. Wiens, and J. A. Stuart, “Molecular mechanisms of oxidative stress resistance induced by resveratrol: specific and progressive induction of MnSOD,” Biochemical and Biophysical Research Communications, vol. 367, no. 2, pp. 406–412, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Lanzilli, A. Cottarelli, G. Nicotera, S. Guida, G. Ravagnan, and M. P. Fuggetta, “Anti-inflammatory effect of resveratrol and polydatin by in vitro IL-17 modulation,” Inflammation, vol. 35, no. 1, pp. 240–248, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Abba, H. Hassim, H. Hamzah, and M. M. Noordin, “Antiviral activity of resveratrol against human and animal viruses,” Advances in Virology, vol. 2015, Article ID 184241, 7 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. I. K. Toliopoulos, Y. V. Simos, S. Oikonomidis, and S. C. Karkabounas, “Resveratrol diminishes platelet aggregation and increases susceptibility of K562 tumor cells to natural killer cells,” Indian Journal of Biochemistry and Biophysics, vol. 50, no. 1, pp. 14–18, 2013. View at Google Scholar · View at Scopus
  21. V. Kirimlioglu, H. Sozen, S. Turkoglu, and M. Haberal, “Protective effect of resveratrol, a red wine constituent polyphenol, on rats subjected to portal vein thrombosis,” Transplantation Proceedings, vol. 40, no. 1, pp. 290–292, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Licinio, M. Principi, G. Losurdo, N. M. Castellaneta, E. Ierardi, and A. Di Leo, “Low molecular weight heparin in portal vein thrombosis of cirrhotic patients: only therapeutic purposes?” The Scientific World Journal, vol. 2014, Article ID 895839, 6 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Wu, Z. Wu, X. Zhang, R. Wang, and J. Bai, “The incidence and risk factors of portal vein system thrombosis after splenectomy and pericardial devascularization,” Turkish Journal of Gastroenterology, vol. 26, no. 5, pp. 423–428, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Primignani, G. Tosetti, and V. La Mura, “Therapeutic and clinical aspects of portal vein thrombosis in patients with cirrhosis,” World Journal of Hepatology, vol. 7, no. 29, pp. 2906–2912, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. K. H. Song, C. S. Youn, C. L. Lee et al., “Increased expression of neuregulin 1 and erbB2 tyrosine kinase in the bladder of rats with cyclophosphamide-induced interstitial cystitis,” International Neurourology Journal, vol. 19, no. 3, pp. 158–163, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. R. H. Raghavendra and K. A. Naidu, “Spice active principles as the inhibitors of human platelet aggregation and thromboxane biosynthesis,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 81, no. 1, pp. 73–78, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Zhang, J. Du, L. Zhao et al., “The role of intraplatelet reactive oxygen species in the regulation of platelet glycoprotein Ibα ectodomain shedding,” Thrombosis Research, vol. 132, no. 6, pp. 696–701, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Momi, R. Caracchini, E. Falcinelli, S. Evangelista, and P. Gresele, “Stimulation of platelet nitric oxide production by nebivolol prevents thrombosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 34, no. 4, pp. 820–829, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. M.-X. Li, X.-F. Zhang, Z.-W. Liu, and Y. Lv, “Risk factors and clinical characteristics of portal vein thrombosis after splenectomy in patients with liver cirrhosis,” Hepatobiliary and Pancreatic Diseases International, vol. 12, no. 5, pp. 512–519, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Kawanaka, T. Akahoshi, N. Kinjo et al., “Impact of antithrombin III concentrates on portal vein thrombosis after splenectomy in patients with liver cirrhosis and hypersplenism,” Annals of Surgery, vol. 251, no. 1, pp. 76–83, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Wang, D. Kopac, R. Brisebois, C. Sample, and A. M. J. Shapiro, “Randomized controlled trial to investigate the impact of anticoagulation on the incidence of splenic or portal vein thrombosis after laparoscopic splenectomy,” Canadian Journal of Surgery, vol. 54, no. 4, pp. 227–231, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. W. Lai, S.-C. Lu, G.-Y. Li et al., “Anticoagulation therapy prevents portal-splenic vein thrombosis after splenectomy with gastroesophageal devascularization,” World Journal of Gastroenterology, vol. 18, no. 26, pp. 3443–3450, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Kawanaka, T. Akahoshi, S. Itoh et al., “Optimizing risk stratification in portal vein thrombosis after splenectomy and its primary prophylaxis with antithrombin III concentrates and danaparoid sodium in liver cirrhosis with portal hypertension,” Journal of the American College of Surgeons, vol. 219, no. 5, pp. 865–874, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Hongwei, L. Zhang, L. Maoping, Z. Yong, D. Chengyou, and L. Dewei, “Era of liver transplantation: combined anatomic splenectomy and anticoagulant therapy in prevention of portal vein thrombosis after splenectomy,” Hepato-Gastroenterology, vol. 62, no. 138, pp. 405–409, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. T. T. Horlocker and J. A. Heit, “Low molecular weight heparin: biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for regional anesthetic management,” Anesthesia and Analgesia, vol. 85, no. 4, pp. 874–885, 1997. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Godihaud, S. Krisa, B. Couronné et al., “Deactivation of cultured human liver myofibroblasts by trans-resveratrol, a grapevine-derived polyphenol,” Hepatology, vol. 31, no. 4, pp. 922–931, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. Z. Wang, J. Zou, Y. Huang, K. Cao, Y. Xu, and J. M. Wu, “Effect of resveratrol on platelet aggregation in vivo and in vitro,” Chinese Medical Journal, vol. 115, no. 3, pp. 378–380, 2002. View at Google Scholar
  38. A. Di Santo, A. Mezzetti, E. Napoleone et al., “Resveratrol and quercetin down-regulate tissue factor expression by human stimulated vascular cells,” Journal of Thrombosis and Haemostasis, vol. 1, no. 5, pp. 1089–1095, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. F. Messina, G. Guglielmini, M. Curini, S. Orsini, P. Gresele, and M. C. Marcotullio, “Effect of substituted stilbenes on platelet function,” Fitoterapia, vol. 105, pp. 228–233, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Gresele, C. Cerletti, G. Guglielmini, P. Pignatelli, G. de Gaetano, and F. Violi, “Effects of resveratrol and other wine polyphenols on vascular function: an update,” Journal of Nutritional Biochemistry, vol. 22, no. 3, pp. 201–211, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. S. T. Towhid, E.-M. Schmidt, E. Schmid et al., “Thymoquinone-induced platelet apoptosis,” Journal of Cellular Biochemistry, vol. 112, no. 11, pp. 3112–3121, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. L.-M. Lien, C.-C. Su, W.-H. Hsu et al., “Mechanisms of andrographolide-induced platelet apoptosis in human platelets: regulatory roles of the extrinsic apoptotic pathway,” Phytotherapy Research, vol. 27, no. 11, pp. 1671–1677, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. K. H. Lin, G. Hsiao, C. M. Shih, D. S. Chou, and J. R. Sheu, “Mechanisms of resveratrol-induced platelet apoptosis,” Cardiovascular Research, vol. 83, no. 3, pp. 575–585, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. F. Violi and P. Pignatelli, “Platelet NOX, a novel target for anti-thrombotic treatment,” Thrombosis and Haemostasis, vol. 111, no. 5, pp. 817–823, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. L.-P. Erwig and P. M. Henson, “Clearance of apoptotic cells by phagocytes,” Cell Death and Differentiation, vol. 15, no. 2, pp. 243–250, 2008. View at Publisher · View at Google Scholar · View at Scopus